Platelet Protein-Related Abnormalities in Response to Acute Hypoglycemia in Type 2 Diabetes.pdf (1.08 MB)
Download file

Platelet protein-related abnormalities in response to acute hypoglycemia in type 2 diabetes

Download (1.08 MB)
journal contribution
posted on 10.02.2022, 16:37 authored by Abu Saleh Md Moin, Ahmed Al-Qaissi, Thozhukat Sathyapalan, Stephen L Atkin, Alexandra E Butler

Introduction: Patients with severe COVID-19 infections have coagulation abnormalities indicative of a hypercoagulable state, with thromboembolic complications and increased mortality. Platelets are recognized as mediators of inflammation, releasing proinflammatory and prothrombotic factors, and are hyperactivated in COVID-19 infected patients. Activated platelets have also been reported in type 2 diabetes (T2D) patients, putting these patients at higher risk for thromboembolic complications of COVID-19 infection.

Methods: A case-control study of T2D (n=33) and control subjects (n=30) who underwent a hyperinsulinemic clamp to induce normoglycemia in T2D subjects: T2D: baseline glucose 7.5 ± 0.3mmol/l (135.1 ± 5.4mg/dl), reduced to 4.5 ± 0.07mmol/l (81 ± 1.2mg/dl) with 1-hour clamp; Controls: maintained at 5.1 ± 0.1mmol/l (91.9 ± 1.8mg/dl). Slow Off-rate Modified Aptamer (SOMA)-scan plasma protein measurement was used to determine a panel of platelet proteins.

Results: Prothrombotic platelet proteins were elevated in T2D versus controls: platelet factor 4 (PF4, p<0.05); platelet glycoprotein VI (PGVI p<0.05); P-selectin (p<0.01) and plasminogen activator inhibitor I (PAI-1, p<0.01). In addition, the antithrombotic platelet-related proteins, plasmin (p<0.05) and heparin cofactor II (HCFII, p<0.05), were increased in T2D. Normalization of glucose in the T2D cohort had no effect on platelet protein levels.

Conclusion: T2D patients have platelet hyperactivation, placing them at higher risk for thromboembolic events. When infected with COVID-19, this risk may be compounded, and their propensity for a more severe COVID-19 disease course increased.

Clinical trial registration: https://clinicaltrials.gov/ct2/show/NCT03102801, identifier NCT03102801.

History

Comments

The original article is available at https://www.frontiersin.org/

Published Citation

Moin ASM, Al-Qaissi A, Sathyapalan T, Atkin SL, Butler AE. Platelet protein-related abnormalities in response to acute hypoglycemia in type 2 diabetes. Front Endocrinol (Lausanne). 2021;12:651009

Publication Date

30 March 2021

PubMed ID

33859620

Department/Unit

  • RCSI Bahrain

Publisher

Frontiers Research Foundation

Version

  • Published Version (Version of Record)